Haemonetics FY2025 EPS Forecast Decreased by Zacks Research

Haemonetics Co. (NYSE:HAE) – Zacks Research cut their FY2025 earnings per share estimates for Haemonetics in a research note issued to investors on Monday, February 17th. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will post earnings per share of $4.56 for the year, down from their prior forecast of $4.58. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics’ Q4 2025 earnings at $1.23 EPS, Q1 2026 earnings at $1.13 EPS, Q2 2026 earnings at $1.24 EPS, Q4 2026 earnings at $1.36 EPS, FY2026 earnings at $5.06 EPS, Q1 2027 earnings at $1.39 EPS, Q2 2027 earnings at $1.47 EPS and FY2027 earnings at $5.83 EPS.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%.

A number of other equities research analysts also recently weighed in on the company. Barrington Research dropped their price objective on Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. JPMorgan Chase & Co. assumed coverage on Haemonetics in a research note on Friday, December 6th. They issued an “overweight” rating and a $116.00 price target for the company. JMP Securities decreased their price target on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research note on Friday, February 7th. StockNews.com cut Haemonetics from a “buy” rating to a “hold” rating in a research note on Saturday, February 15th. Finally, Needham & Company LLC decreased their price target on Haemonetics from $112.00 to $108.00 and set a “buy” rating for the company in a research note on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $101.67.

Haemonetics Price Performance

Shares of HAE stock opened at $63.88 on Wednesday. Haemonetics has a 1-year low of $58.80 and a 1-year high of $97.97. The stock’s 50-day moving average is $73.37 and its 200 day moving average is $76.85. The company has a market cap of $3.21 billion, a P/E ratio of 25.15, a PEG ratio of 1.09 and a beta of 0.39. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of HAE. TD Waterhouse Canada Inc. purchased a new position in shares of Haemonetics in the fourth quarter worth about $25,000. Covestor Ltd raised its stake in shares of Haemonetics by 146.8% in the fourth quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier’s stock worth $58,000 after purchasing an additional 439 shares during the last quarter. Whittier Trust Co. purchased a new position in shares of Haemonetics in the fourth quarter worth about $62,000. Nisa Investment Advisors LLC raised its stake in shares of Haemonetics by 124.2% in the third quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock worth $92,000 after purchasing an additional 632 shares during the last quarter. Finally, Parkside Financial Bank & Trust raised its stake in shares of Haemonetics by 25.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock worth $92,000 after purchasing an additional 240 shares during the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.